Eliminating the need of serum testing using low serum culture conditions for human bone marrow-derived mesenchymal stromal cell expansion
Open Access
- 20 February 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in BioMedical Engineering OnLine
- Vol. 12 (1), 15
- https://doi.org/10.1186/1475-925x-12-15
Abstract
The conventional expansion of human mesenchymal stromal cells (hMSC) for tissue engineering or (pre-) clinical investigation includes the use of 10% fetal bovine serum (FBS). However, there exists immense lot-to-lot variability in FBS samples and time consuming as well as cost intensive lot pre-testing is essential to guarantee optimal hMSC proliferation and stem cells characteristics maintenance. Furthermore, lot-to-lot variability impedes the long-term consistency of research and comparability between research groups. Therefore, we investigated the use of defined, invariable, non-synthetic FBS in low serum culture conditions for isolation and expansion of hMSC. hMSC were isolated from bone marrow in Panserin 401 supplemented with growth factors and 2% MSC-tested or non-tested, defined, invariable, non-synthetic FBS and further cultivated in vitro. The surface marker expression, differentiation capacity as well as cell proliferation and cytotoxicity was analyzed and compared between serum samples. Cells isolated and cultivated with low concentrations of MSC-tested or non-tested FBS demonstrated no differences in surface marker expression or differentiation capacity. Proliferation of hMSC was equal in medium supplemented with either serum with no indication of cell death. The low serum concentration in Panserin 401 supplemented with growth factors enables the use of defined, invariable, non-synthetic FBS for the isolation and expansion of hMSC. The required hMSC characteristics like surface marker expression and differentiation capacity are maintained. Importantly, no differences in the cell proliferation could be detected. Therefore, using these low-serum culture conditions, the need for lot-to-lot pre-testing of FBS usually needed for optimal hMSC expansion is abolished leading to long-term consistency and comparability of results.Keywords
This publication has 28 references indexed in Scilit:
- Mesenchymal stem cell transplantation for the infarcted heart: a role in minimizing abnormalities in cardiac-specific energy metabolismAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cellsJournal of Translational Medicine, 2011
- Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosisMultiple Sclerosis Journal, 2009
- Donor-Derived Mesenchymal Stem Cells Suppress Alloreactivity of Kidney Transplant PatientsTransplantation, 2009
- Autologous Bone Marrow Transplantation in Patients with Subacute and Chronic Spinal Cord InjuryCell Transplantation, 2006
- Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patientsCytotherapy, 2006
- Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis ImperfectaTransplantation, 2005
- Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarctionThe American Journal of Cardiology, 2004
- Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activationBone Marrow Transplantation, 2004
- Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfectaBlood, 2001